FDA Approves Novartis' Biosimilar Erelzi

Mullenix & Associates LLC client Novartis received approval from the U.S. Food and Drug Administration for their new biosimilar arthritis treatment, Erelzi (a lower priced version of Amgen's Enbrel). Biosimilars can "slash the cost of treating diseases such as cancer, diabetes and rheumatoid arthritis, potential saving health-care systems in the U.S. and the European Union more than 50 billion euros ($56 billion USD) over the next five years", according to IMS Health.

Full story below.